Nature Immunology, Journal Year: 2021, Volume and Issue: 22(9), P. 1140 - 1151
Published: Aug. 23, 2021
Language: Английский
Nature Immunology, Journal Year: 2021, Volume and Issue: 22(9), P. 1140 - 1151
Published: Aug. 23, 2021
Language: Английский
Nature reviews. Immunology, Journal Year: 2021, Volume and Issue: 21(6), P. 347 - 362
Published: Jan. 13, 2021
Language: Английский
Citations
370Cell, Journal Year: 2020, Volume and Issue: 180(4), P. 749 - 763.e13
Published: Feb. 1, 2020
Language: Английский
Citations
330Cell Host & Microbe, Journal Year: 2021, Volume and Issue: 29(7), P. 1076 - 1092
Published: May 21, 2021
Language: Английский
Citations
299Nature reviews. Immunology, Journal Year: 2020, Volume and Issue: 20(11), P. 709 - 713
Published: Oct. 6, 2020
Language: Английский
Citations
264Immunological Reviews, Journal Year: 2022, Volume and Issue: 310(1), P. 6 - 26
Published: June 5, 2022
Antibodies against epitopes in S1 give the most accurate CoP infection by SARS-CoV-2 coronavirus. Measurement of those antibodies neutralization or binding assays both have predictive value, with antibody titers giving highest statistical correlation. However, protective functions are multiple. multiple other than influence efficacy. The role cellular responses can be discerned respect to CD4
Language: Английский
Citations
244Nature Reviews Clinical Oncology, Journal Year: 2020, Volume and Issue: 17(6), P. 341 - 348
Published: Feb. 28, 2020
Language: Английский
Citations
238Journal for ImmunoTherapy of Cancer, Journal Year: 2019, Volume and Issue: 7(1)
Published: Oct. 17, 2019
The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After first indication melanoma, an increasing list additional types are now treated with system targeting antibodies PD-1, PD-L1 and CTLA-4, alleviating inhibition signals on T cells. Recently, we published proof-of-concept results novel inhibitor, NKG2A. This receptor is expressed cytotoxic lymphocytes, including NK cells subsets activated CD8+ Blocking NKG2A unleashed reactivity these effector resulting tumor control multiple mouse models early clinical trial. Monalizumab inhibiting this human beings future trials will have reveal its potency combination other treatment options.
Language: Английский
Citations
237Nature Immunology, Journal Year: 2020, Volume and Issue: 21(4), P. 412 - 421
Published: Feb. 17, 2020
Language: Английский
Citations
224Cell, Journal Year: 2021, Volume and Issue: 184(6), P. 1575 - 1588
Published: March 1, 2021
Language: Английский
Citations
212Nature Reviews Methods Primers, Journal Year: 2022, Volume and Issue: 2(1)
Published: Feb. 10, 2022
Language: Английский
Citations
209